Sandoz Group AG
SDZ | SW
Overview
Corporate Details
- ISIN(s):
- CH1243598427 (+2 more)
- LEI:
- 5493000JWK6XWFEUD320
- Country:
- Switzerland
- Address:
- Suurstoffi 14, 6343 Rotkreuz
- Website:
- https://www.sandoz.com/
- Sector:
- Human health and social work activities
- Industry:
- Hospital activities
Description
Sandoz operates in the attractive and growing global off-patent medicines market, which benefits from a growing and aging population, higher rates of chronic disease, increasing market adoption as healthcare systems and payors seek to reduce the cost of medicines, and a consistent supply of upcoming loss of exclusivities (LoEs) as patents for originator products expire. Together, these drivers are expected to support long-term growth in volumes that will more than offset anticipated erosion in price.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Sandoz Group AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-28 07:00 |
Regulatory News Service
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antith…
|
English | 19.4 KB | |
| 2025-08-28 02:00 |
Regulatory News Service
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antith…
|
English | 17.3 KB | |
| 2025-08-12 02:00 |
Environmental & Social Information
Sandoz launches renewable energy partnership to cover nearly 90% of electricity…
|
English | 5.5 KB | |
| 2025-08-07 02:00 |
Earnings Release
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the se…
|
English | 67.1 KB | |
| 2025-07-01 02:00 |
Capital/Financing Update
Sandoz further asserts leadership in biosimilars, breaking ground on new Sloven…
|
English | 7.7 KB | |
| 2025-06-02 02:00 |
Regulatory News Service
Sandoz launches first and only interchangeable denosumab biosimilars in US, pro…
|
English | 19.9 KB | |
| 2025-05-21 02:00 |
Regulatory News Service
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe …
|
English | 10.8 KB | |
| 2025-03-05 01:00 |
Annual Report
Sandoz reports strong FY 2024 results and Q4 2024 sales
|
English | 83.1 KB | |
| 2025-02-24 01:00 |
Earnings Release
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new…
|
English | 21.0 KB | |
| 2025-02-03 01:00 |
Board/Management Information
Francisco Ballester to retire; Peter Stenico appointed President Region Interna…
|
English | 5.4 KB | |
| 2025-01-14 01:00 |
Earnings Release
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd An…
|
English | 11.2 KB | |
| 2024-12-17 01:00 |
Legal Proceedings Report
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Ac…
|
English | 7.6 KB | |
| 2024-11-15 01:00 |
Regulatory News Service
Sandoz receives European Commission approval for Afqlir® (aflibercept), further…
|
English | 7.2 KB | |
| 2024-10-30 01:00 |
Earnings Release
Sandoz reports third-quarter and nine-month 2024 sales
|
English | 32.6 KB | |
| 2024-08-12 02:00 |
Regulatory News Service
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthe…
|
English | 9.9 KB |
Automate Your Workflow. Get a real-time feed of all Sandoz Group AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Sandoz Group AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 54,000.00 CHF |
| 2023-11-17 | N/A | Non-Executive member | Buy | None | 988,797.00 CHF |
| 2023-11-17 | N/A | Non-Executive member | Buy | None | 200,493.50 CHF |
| 2023-11-10 | N/A | Non-Executive member | Buy | None | 84,583.00 CHF |
| 2023-11-10 | N/A | Non-Executive member | Buy | None | 72,917.00 CHF |
| 2023-11-10 | N/A | Non-Executive member | Buy | None | 13,417.00 CHF |
| 2023-10-25 | N/A | Executive member | Buy | None | 486,590.00 CHF |
